A B-cell acute lymphoblastic leukemia (B-ALL) patient with positive Philadelphia chromosome relapsed after CD19-CAR-T cell therapy and was treated with a combination of blinatumomab (a bispecific T cell binding agent for CD19 and CD3) and ponatinib (a polytyrosine kinase inhibitor) and achieved a continuous remission of 12 months [62, 63]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.